SESSION TITLE: Student/Resident Case Report Poster - Pulmonary Vascular Disease II
SESSION TYPE: Student/Resident Case Report Poster
PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM
INTRODUCTION: Dasatinib is a tyrosine-kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia (CML). While pleural effusions are a common adverse effect of dasatinib treatment, dasatinib-induced PAH is rare. Typically the PAH resolves just by discontinuation of dasatinib, however, the appropriate treatment strategy for patients who have decompensated to a New York Heart Association class IV functional (FC) status is unclear.